Legless Chinese shoemaker impresses public with English fluency, dreams of delivering speech at Harvard
CHINA: In the crowded and buzzing streets of Heyuan, Guangdong province, a 44-year-old shoemaker without legs is rousing China with his extraordinary account of determination, self-learning, and imaginings that reach all the way to Harvard.
According to a recent South China Morning Post (SCMP) report, Huang Huaquan lost both legs in a heart-rending accident when he was six, hit by a truck at a countryside market. Compelled to leave school after primary education due to his infirmity, Huang didn't give up on acquiring knowledge and continued learning. Obsessed with the English language, he rented or borrowed old schoolbooks and taught himself through radio programs and cassette tapes.
Notwithstanding physical challenges, Huang became a lauded incapacitated bodybuilder, winning gold awards at provincial sports events. But for almost a decade, his concentration has shifted to mending shoes and fixing umbrellas on the street, a low-key but honest trade that permitted him to purchase both a car and an apartment.
'What doesn't kill me makes me stronger,' Huang said. 'Many things take more effort for me, but I still have my hands—and my will.'
Ridiculed by many for studying English in his free time, Huang vigorously continued with much determination and persistence. In 2024, he published a book and launched video lessons in spoken English, sharing his diligently gained methods with others.
Today, he has a new goal: to be on one of the world's most respected podiums and share his narrative at Harvard University.
'If I ever get the chance, I'll speak about how an ordinary man used his hands to climb out of darkness and find a glimmer of light,' he said. 'Even if my story helps just one person, it's worth it.'
His story has already caught the attention of the Harvard Alumni Association in Beijing. Xu Liang, head of the association, is initiating an event where Huang could speak to hundreds of graduates. Discussions are also in progress to see if he might one day address the university itself.
'I deeply admire his determination and his dignity in facing life's hardships,' Xu said in a video compliment. See also Marvel's first Chinese superhero Shang-Chi gets China excited
Still unattached, Huang dreams not only of Harvard but of one day getting married and starting a family.
'It won't be easy,' he admits. 'But I must be strong and capable—so I can support myself and the people I love.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Independent Singapore
3 days ago
- Independent Singapore
Hong Kong's China Medical System Holdings plans SGX secondary listing
SINGAPORE: Hong Kong-listed China Medical System Holdings (CMS) plans a secondary listing on the Mainboard of the Singapore Exchange (SGX), with shares set to trade in July 2025. This is part of its regional expansion strategy to tap investors in the city-state and expand in Southeast Asia's fast-growing healthcare market. The secondary listing is expected to raise its profile and tap a pool of sophisticated healthcare and life sciences investors. The firm has already secured a letter of eligibility from the Singapore bourse. China Medical System is part of the Hang Seng Large-Mid Cap (Investable) Index. Since 2023, it's also been part of the Hang Seng Innovative Drug Index. This is due to its evolving focus on cutting-edge therapies. The last two years have been challenging for the company due to the impact of Beijing's stand on volume-based procurement (VBP) policy. Designed to reduce the cost of drugs and medical devices, the VBP scheme has driven steep price competition, affecting firms with more traditional product lines. This led CMS to transition to an innovation-led business model that focuses on high-value, clinically driven products. According to company reports, it's in gradual recovery from the effects of VBP. It predicts renewed growth momentum, with a pipeline of approximately 40 innovative projects as of the end of 2024. With a regional population close to 700 million, Southeast Asia's growing demand for medicine is fuelled by a mix of factors. This includes a growing regional middle class, the spread of lifestyle diseases, and ageing demographics in countries like Singapore and Thailand. CMS will tap this market through two entities. The first is Singapore-based Rxilient Health, a regional unit focused on global licensing and commercialisation of pharmaceuticals. The second is CMS's associated firm, PharmaGend Global, which has acquired a Singapore-based contract development and manufacturing organisation (CDMO). This facility spans over 60,000 square metres and can produce up to 1 billion tablets and capsules annually. Rxilient Health has operations in Malaysia, Vietnam, Indonesia, the Philippines, and Thailand. This will enable market localisation, while commercial production in Singapore, which began at the end of 2024, will enable supply to regional customers. The Singapore facility has received a Good Manufacturing Practice certification from the US Food and Drug Administration (FDA) and passed inspections by Singapore's Health Sciences Authority (HSA). FY2024 saw China Medical System face significant financial challenges. Its earnings dropped by 32.5% compared to the previous year, falling to RMB 1.62 billion (~US$288 million or S$367 million). This also saw a decline in gross profit (11.2%) as well as net profit (32.3%). The company is banking on its investments in innovation and overseas market expansion to drive future recovery and growth. The timing of the secondary listing comes amid strong momentum on the Singapore bourse. SGX shares rose 7.2% last week, hitting a five-year high of S$14.72 on Jun 27. The Straits Times Index (STI) closed the week at 3,966.20, up 0.7%. Investors appear to be leaning on Singapore's stability as global concerns over inflation, oil prices, and tariffs continue. Trading activity has picked up noticeably, especially in the small and mid-cap segments.
CNA
5 days ago
- CNA
WHO says all Covid-19 origin theories still open, after inconclusive study
GENEVA: All hypotheses on how the Covid-19 pandemic began remain open, the World Health Organization said on Friday (Jun 27), following an inconclusive four-year investigation that was hamstrung by crucial information being withheld. The global catastrophe killed an estimated 20 million people, according to the WHO, while shredding economies, crippling health systems and turning people's lives upside-down. The first cases were detected in Wuhan in China in late 2019, and understanding where the SARS-CoV-2 virus that causes Covid came from is key to preventing future pandemics. However, a lengthy investigation launched by the UN's health agency said that pending further data, the origin of Covid and how it first spread remains elusive. "As things stand, all hypotheses must remain on the table, including zoonotic spillover and lab leak," WHO chief Tedros Adhanom Ghebreyesus told a press conference, referring to the two main hypotheses as to how the pandemic began. EXPERT INVESTIGATION An initial WHO-Chinese joint report in March 2021 concluded that the virus most likely jumped from bats to humans via an intermediate animal. It deemed a leak from Wuhan's virology laboratories, known for their research on coronaviruses, to be "extremely unlikely". However, that investigation faced harsh criticism for lacking transparency and access, and for not seriously evaluating the lab-leak theory. Tedros launched another investigation, setting up the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), comprising 27 international experts, in July 2021. Their 78-page report was published on Friday. It said the weight of available evidence suggests a spillover from animals, either directly from bats, or through an intermediate host. However, it could not conclude with certainty where and when this happened, nor whether the Wuhan wet market was where the virus first spilled over into humans. That said, the market "appears to be the location for amplification of infection in humans", leading to widespread transmission. "Evidence for widespread infections or cases in any other countries prior to December 2019 is lacking," it added. While spillover was the best supported theory on the evidence currently available, "until further requests for information are met, or more scientific data becomes available, the origins of SARS-CoV-2 and how it entered the human population will remain inconclusive," SAGO chair Marietjie Venter said at the press conference. Lab leak theories "could not be investigated or excluded", she said, because much of the needed information had not been made available. The experts requested unpublished information from other countries, notably Germany and the United States, but without success, she said. Earlier this week, one SAGO member resigned and three others asked for their names to be removed from the report. CRUCIAL QUESTION "Over the past five years, we have learned a lot about Covid-19 but there is one crucial question about the pandemic that we have not yet answered, how it started," Tedros said. "Despite our repeated requests, China has not provided hundreds of viral sequences from individuals with Covid-19 early in the pandemic, more detailed information on animals sold at markets in Wuhan, and information on work done and biosafety conditions at laboratories in Wuhan," he said. He said WHO has requested access to intelligence reports by governments around the world on the origins of Covid-19. US President Donald Trump's administration has officially embraced the lab leak theory. MORAL IMPERATIVE Tedros said finding out how Covid-19 started was a moral imperative for those who lost their lives in the pandemic and to prevent further outbreaks. He said the virus was continuing to evolve, take lives and leave people suffering with post-Covid conditions, or so-called long Covid. Tedros said the WHO is appealing to countries with information about the origins of Covid-19 to share information.
Straits Times
7 days ago
- Straits Times
6 million donkeys slaughtered for Chinese health supplement, charity says
Criminal networks have moved in since the African Union issued a moratorium on donkey slaughter in 2024. PHOTO: AFP ADDIS ABABA, Ethiopia – Almost six million donkeys are slaughtered annually for Chinese medicine, with severe knock-on effects for African villagers who rely on the animals, a Britain-based charity said on June 26. It is driven by an increase in China's production of ejiao – a product marketed as a health supplement that uses collagen from donkey skins – which is a US$6.8 billion (S$8.6 billion) industry, according to China-based research firm Qianzhan. China, whose donkey population has plummeted from 11 million in 1992 to 1.5 million in 2023, has turned to Africa to meet its demand. With donkey populations falling, the African Union issued a 15-year moratorium on donkey slaughter in 2024. Britain-based charity The Donkey Sanctuary said 'the ejiao industry drives a massive global trade in donkey skins, much of it illegal'. It said around 5.9 million donkeys were killed worldwide in 2024. The ejiao trade is expected to require at least 6.8 million donkey skins by 2027. The rising value of donkeys means they have increasingly become targets for criminals. 'Traders exploit vulnerable people using large and sophisticated networks of agents to pressure donkey owners into selling their animals,' the charity said. 'Illegal networks operate across the continent, often without consequence, stealing and slaughtering donkeys in the night,' it added. 'Donkeys die in often unregulated, inhumane and unsanitary conditions, and large numbers perish on their way to slaughterhouses,' it said. The impact on humans is particularly felt by women and children, who rely on donkeys for farming activities such as ploughing and for carrying goods to market. The criminal operations also generated health risks, The Donkey Sanctuary said. 'The transportation of untreated skins and improper disposal of donkey carcasses risk triggering the spread of infectious diseases and damaging local ecosystems.' AFP Join ST's Telegram channel and get the latest breaking news delivered to you.
